Li Y, Sun H, Guan J, Ji T, Wang X. Serum microRNA-381: A Potential Marker for Early Diagnosis of Gastric Cancer.
Yonsei Med J 2019;
60:720-726. [PMID:
31347326 PMCID:
PMC6660439 DOI:
10.3349/ymj.2019.60.8.720]
[Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 06/05/2019] [Accepted: 06/18/2019] [Indexed: 12/31/2022] Open
Abstract
PURPOSE
The purpose of this study was to explore the potential early diagnostic value of serum microRNA-381(miRNA-381) in patients with gastric cancer (GC).
MATERIALS AND METHODS
Patients with advanced gastric cancer (AGC) and early gastric cancer (EGC), as well as healthy individuals, were enrolled in this study. Expression of miRNA-381 in serum was detected using real-time quantitative PCR. Electrochemiluminescence analysis was used to investigate the expression of classic tumor markers, including carbohydrate antigen (CA) 199, CA724, and carcinoembryonic antigen. Finally, receiver operating characteristic curve and Kaplan-Meier analysis were used to determine the value of miRNA-381 in clinical diagnosis of GC.
RESULTS
miRNA-381 was differentially expressed among the study groups. AUC analysis showed that the sensitivity and specificity of serum miRNA-381 in the diagnosis of GC were superior to those of other tumor markers. Furthermore, low levels of miRNA-381 expression were positively correlated with lymph node metastasis and AGC. Finally, Kaplan-Meier survival analysis showed that down-regulation of miRNA-381 was associated with lymph node metastasis and the development of GC.
CONCLUSION
miRNA381, which was down-regulated in GC, might be a novel early diagnosis marker for patients with GC.
Collapse